Abstract:Pei Wang, 1, 2, &ast Ming-Hao Xu, 3, &ast Wen-Xin Xu, 3, &ast Zi-Ying Dong, 4 Ying-Hao Shen, 3 Wen-Zheng Qin 1 1 Endoscopy Center and Endoscopy Research Institute, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China; 2 Department of Digestive Medicine, Wuwei People's Hospital, Wuwei City, Gansu Province, 733000, People's Republic of China; 3 Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China; 4 Department of CT/MRI Center, Wuwei People's Hospital, Wuwei City, Gansu Province, 733000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wen-Zheng Qin, Endoscopy Center and Endoscopy Research Institute, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China, Tel/Fax +86-21-64041990, Email Ying-Hao Shen, Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital, Fudan University, No. 180, Fenglin Road, Shanghai, 200032, People's Republic of China, Tel/Fax +86-21-64041990, Email Background: Anti-programmed death-1 (PD1) antibodies have changed the treatment landscape for hepatocellular carcinoma (HCC) and exhibit promising treatment efficacy. However, the majority of HCCs still do not respond to anti-PD-1 therapy. Methods: We analyzed the expression of CXCL9 in blood samples from patients who received anti-PD-1 therapy and evaluated its correlation with clinicopathological characteristics and treatment outcomes. Based on the results of Cox regression analysis, a nomogram was established for predicting HCC response to anti-PD-1 therapy. qRT‒PCR and multiple immunofluorescence assays were utilized to analyze the proportions of N1-type neutrophils in vitro and in tumor samples, respectively. Results: The nomogram showed good predictive efficacy in the training and validation cohorts and may be useful for guiding clinical treatment of HCC patients. We also found that HCC cell-derived CXCL9 promoted N1 polarization of neutrophils in vitro and that AMG487, a specific CXCR3 inhibitor, significantly blocked this process. Moreover, multiple immunofluorescence (mIF) showed that patients with higher serum CXCL9 levels had greater infiltration of the N1 phenotype of tumor-associated neutrophils (TANs). Conclusion: Our study highlights the critical role of CXCL9 as an effective biomarker of immunotherapy efficacy and in promoting the polarization of N1-type neutrophils; thus, targeting the CXCL9-CXCR3 axis could represent a novel pharmaceutical strategy to enhance immunotherapy for HCC. Keywords: CXCL9, anti-PD-1 antibody, N1 polarization of neutrophils, nomogram Hepatocellular carcinoma (HCC) is the most common type of liver cancer and is often diagnosed at advanced stages when surgical resection is contraindicated. 1 Therefore, systemic treatment is the main treatment option for patients with advanced HCC. Standard first-line treatment options for HCC typically include sorafenib, lenvatinib, and other kinds of immunotherapy. In addition, combination treatment regimens have shown promising results. Atezolizumab in combination with bevacizumab is now recommended based on the IMbrave150 Phase III trial results. 2,3 Other combinations, such as targeted therapy combined with immunotherapy or immunotherapy combined with antiangiogenic drugs, are being rigorously evaluated for their efficacy and adverse effects in large clinical trials. 4 In theory, due to the different mechanisms of action of two drugs in a combination therapy, synergistic effects can be exerted to maximize the antitumor benefits. Moreover, toxicity is not additive. 5 In addition, with the advancements in systematic treatment, neoadjuvant therapy and adjuvant therapy for HCC have also received increasing amounts of attention. 6 The postoperative adjuvant atezolizumab combined with bevacizumab has also been proven to prolong the progression-free survival of HCC patients. 7 The PD-1/PD-L1 pathway represents a key immune checkpoint that tumors utilize to evade immune surveillance. Thus, blockade of the PD-1/PD-L1 pathway has revolutionized cancer immunotherapy, leading to significant improvements in patient outcomes across multiple tumor types, including HCC. 8 PD-1 inhibitors, such as nivolumab 9 and pembrolizumab, 10 have shown promising activity in the treatment of HCC. These agents restore the function of T cells, unleashing the immune system on tumors and leading to durable tumor res -Abstract Truncated-

Cyclin Dependent Kinase 9 Inhibition Reduced Programmed Death-Ligand 1 Expression and Improved Treatment Efficacy in Hepatocellular Carcinoma

Abstract 5985: Cyclin Dependent Kinase 9 (CDK9) Inhibition Increased Efficacy of Programmed Cell Death Protein 1 (PD-1) Blockade for Hepatocellular Carcinoma (HCC) Through Decreasing Programmed Death-Ligand 1 (PD-L1) Expression

Cyclin-Dependent Kinase 9 Inhibition As a Potential Treatment for Hepatocellular Carcinoma

Potent Activity of Composite Cyclin Dependent Kinase Inhibition Against Hepatocellular Carcinoma

Abstract 2831: Composite Cyclin Dependent Kinase Inhibition Shows Potent Activity Against Hepatocellular Carcinoma

CDK5 destabilizes PD-L1 via chaperon-mediated autophagy to control cancer immune surveillance in hepatocellular carcinoma

Inhibition of PCSK9 enhances the anti-hepatocellular carcinoma effects of TCR-T cells and anti-PD-1 immunotherapy

Inhibition of CDK9 exhibits anticancer activity in hepatocellular carcinoma cells via targeting ribonucleotide reductase

Pd-1 And Pd-L1 Upregulation Promotes Cd8(+) T-Cell Apoptosis And Postoperative Recurrence In Hepatocellular Carcinoma Patients

Increased CD8+ T-cell Infiltration and Efficacy for Multikinase Inhibitors After PD-1 Blockade in Hepatocellular Carcinoma

Hepatic interferon regulatory factor 8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti–programmed cell death protein‐1 therapy

Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma

CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer

CXCL9 Overexpression Predicts Better HCC Response to Anti-PD-1 Therapy and Promotes N1 Polarization of Neutrophils

Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy

Inhibition of CDK9 Induces Apoptosis and Potentiates the Effect of Cisplatin in Hypopharyngeal Carcinoma Cells

Abstract 417: Role of programmed cell death protein-1 (PD-1)-targeted immunotherapy in hepatocellular carcinoma

Dual Programmed Death Receptor‐1 and Vascular Endothelial Growth Factor Receptor‐2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma

Combination CXCR4 and PD1 blockade enhances intratumoral dendritic cell activation and immune responses against hepatocellular carcinoma

Programmed Cell Death‐1 (PD‐1) Checkpoint Blockade in Combination with a Mammalian Target of Rapamycin Inhibitor Restrains Hepatocellular Carcinoma Growth Induced by Hepatoma Cell–intrinsic PD‐1

PD-L1 expression on circulating tumor cells can be a predictive biomarker to PD-1 inhibitors combined with radiotherapy and antiangiogenic therapy in advanced hepatocellular carcinoma